Skip to main content
TEVA logo

Teva Pharmaceutical Industries Limited (TEVA) Stock: Price, Forecast & Analyst Target

Teva Pharmaceutical Industries Limited (TEVA) — MoonshotScore 57/100 (Fair band), calculated Nov 18, 2026. Price $38.54 (-8.74%), as of the Nov 19, 2026 trading session; market cap $45.0B.

Educational signal · not a buy or sell recommendation · How to read this

$38.54 −$3.69 (-8.74%) Market Cap $45.0B

Teva Pharmaceutical Industries Limited · TEVA · NYSE · Healthcare · Drug Manufacturers - Specialty & Generic

Research dated 2026-09-12: Teva is a global medicine manufacturer whose revenue comes chiefly from products spanning generics, specialty drugs, biopharmaceuticals, and active pharmaceutical ingredients, with smaller distribution and licensing streams. Product growth and cash generation must overcome uneven reported profit and debt that stands far above available liquidity.

Price as of Nov 19, 2026

Key Statistics

57 of 100

MoonshotScore v2 · Teva Pharmaceutical Industries (TEVA)

Fair
Business Quality Solid (76)
Financial Safety Strained (24)
Valuation Full (44)
Growth Durability Growing (77)
Momentum Surging (93)
Why this rating? Method, drivers & history

Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.

  • Business Quality — Is this a genuinely good business?
  • Financial Safety — Could this blow up on me?
  • Valuation — Am I paying a fair price?
  • Growth Durability — Is the growth real and likely to last?
  • Momentum — Is the market already moving on this?
The ten-second read ·

High quality and durable growth, but a fragile balance sheet and a full valuation; the market is already moving on it. The score also carries a risk penalty for a bankruptcy-risk score in the distress zone. Business Quality: Solid; Financial Safety: Strained; Valuation: Full; Growth Durability: Growing; Momentum: Surging.

  • Altman Z 0.94 · Piotroski F 7
  • ROE 6.4% · ROA 1.3% · current ratio 0.95 · earnings yield 1.0% · free-cash-flow yield 2.4%

Holding back: balance-sheet strain

Helping: business quality, durable growth, positive momentum

What has the MoonshotScore done over time?

MoonshotScore snapshots recorded for TEVA (52 recorded, newest six shown)
RecordedScoreBand
60Fair
61Fair
62Fair
62Fair
57Fair
57Fair

Daily score refresh is delayed. This is the last recorded calculation.

Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.

Computed · How the MoonshotScore is computed →

Price & valuation

Dates shown where recorded
MeasureValueAs of
Latest provided price$38.54
Change on the day-8.74%
52-week range$24.01–$44.57
Market capitalisation$45.0B—
Price / earnings (trailing)94.71
Shares traded on the day10.34M
Beta (volatility vs the S&P 500)0.84

Price & events

Weekly closing price with reported quarters marked Weekly closing price from Oct 17, 2025 to Nov 19, 2026: low $19, high $45, latest $39. $45 $19 high $45 Oct 17, 2025 Nov 19, 2026 · $39 $19Oct 17, 2025$20Oct 31, 2025$25Nov 14, 2025$27Nov 28, 2025$30Dec 12, 2025$32Dec 26, 2025$32Jan 9, 2026$32Jan 23, 2026$35Feb 6, 2026$34Feb 20, 2026$31Mar 6, 2026$29Mar 20, 2026$30Apr 2, 2026$32Apr 17, 2026$35May 1, 2026$34May 15, 2026$35May 29, 2026$35Jun 12, 2026$33Jun 26, 2026$33Jul 10, 2026$31Jul 24, 2026$35Aug 7, 2026$37Aug 21, 2026$36Sep 4, 2026$39Sep 18, 2026$40Oct 2, 2026$42Oct 16, 2026$42Oct 30, 2026$45Nov 13, 2026

Point at or tab to any week for its close.

Other perspectives

Council score for Teva Pharmaceutical Industries (TEVA): perspectives

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

5-Factor Breakdown

Business Quality Moderate
Financial Safety Weak
Valuation Neutral
Growth Durability Moderate
Momentum Strong

Legends Council

5 lenses, 0 current

AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built

Dalio-style lens (simulated) Ray Dalio Favorable read
Griffin-style lens (simulated) Ken Griffin Favorable read
Englander-style lens (simulated) Izzy Englander Favorable read
Klarman-style lens (simulated) Seth Klarman Neutral read
Moon AI lens (model) Favorable read

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

Munger's Mindset

Balance Sheet & Valuation · historical

Financial Health Weak
Margin of Safety Fairly Valued
Profit Margin Weak
Debt/Equity Negative
ROE Neutral
Gross Margin Moderate

Read on: Nov 17, 2026 · older than the 27 hours refresh window; not a current reading

How to read these bars and different assessments

Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.

Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.

On Nov 17, 2026, the Munger lens read the price at that time as fairly valued against its own estimate of value.

Readings on this page are from Nov 20, 2026, except a card that shows its own read date.

1 · What is it?

What is Teva Pharmaceutical Industries (TEVA), and what does it report?

Short answer · as of

Calling Teva merely a generic-drug maker leaves out branded franchises such as AUSTEDO, AJOVY, and Copaxone, a broad respiratory and oncology portfolio, active pharmaceutical ingredients, and long-acting injectable development.

Reported revenue is overwhelmingly product sales, supplemented by distribution services, licensing, and other activities, so demand reflects prescriptions, customer orders, portfolio pricing, and commercial partnerships rather than a royalty stream alone.

2 · Latest results

What do the latest results show for Teva Pharmaceutical Industries (TEVA)?

The latest period delivered higher revenue and gross profit than the preceding period, yet operating profit contracted sharply and the net result swung to a loss. Revenue exceeded the consensus estimate while the reported earnings measure missed it, and operating cash flow recovered from an outflow even as profit conversion deteriorated.

Management expects operating expenses to normalize as transformation savings gain impact and continues to guide toward its stated gross-margin band. It has separately warned that AUSTEDO faces weaker purchasing patterns and a tougher pricing environment ahead of IRA implementation, making that product a specific pressure rather than evidence of portfolio-wide demand weakness.

Where is operating spending going?

Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.

Period endRevenueR&DSG&AFMP standardized operating result
Sep 30, 2026Not availableNot availableNot availableNot available
Jun 30, 2026Not availableNot availableNot availableNot available
Mar 31, 2026Not availableNot availableNot availableNot available
Dec 31, 2025Not availableNot availableNot availableNot available
How to read these figures

Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.

Quarterly income statement — 4 quarters
Revenue, net income and earnings per share by quarter
PeriodRevenueNet incomeEPS
Sep 2025$4.48B$433M$0.37 (diluted)
Q4 FY2025$4.71B$480M$0.41 (diluted)
Q1 FY2026$3.98B$369M$0.31 (diluted)
Q2 FY2026$4.14B-$576M-$0.49 (diluted)
3 · Financial strengths and risks

What are the financial strengths and risks for Teva Pharmaceutical Industries (TEVA)?

Short answer · as of

Cash and short-term investments were $0.00 at the Sep 30, 2026 balance-sheet date. This figure does not establish a cash runway.

Teva returned to annual profitability after a run of losses, and recent operating cash flow shows the business can generate substantial cash. That strength is irregular: cash flow has moved between outflows and strong inflows, while quarterly earnings have also shifted between profit and loss.

The cash balance sits near the upper end of its recent range and is concentrated in cash and short-term investments, but debt remains far larger. Positive trailing margins and a healthy free-cash-flow yield coexist with modest net profitability, elevated leverage, and conflicting distress and quality screens; renewed AUSTEDO pressure or weak profit conversion would make that debt burden harder to reduce.

Data-derived red flags

  • Financial-distress signal — its Altman Z-Score of 0.94 sits in the distress zone (elevated bankruptcy risk).
  • Rich valuation — a P/E of 94.71 runs well above the Healthcare sector’s ~21.70x, leaving little room for a miss.
4 · What to check next?

What should you watch next at Teva Pharmaceutical Industries (TEVA)?

Short answer · as of

Current published price targets run low $44.00 · high $54.00 · consensus $48.22 · median $48.00 against a quoted price of $38.54 (as of Nov 19, 2026).

At the upcoming earnings release, track whether revenue again clears expectations and whether that strength reaches operating profit, reported earnings, and operating cash flow. Gross-margin delivery and the promised normalization of operating expenses would provide direct evidence that transformation savings are reaching the income statement.

AUSTEDO deserves separate attention because management expects purchasing and pricing pressure tied to IRA implementation. Longer-range consensus estimates assume rising revenue and earnings, so sustained product growth alongside steadier cash conversion would support that path; another disconnect between sales and profit would challenge it.

What the records here don't tell us

  • No forward revenue or earnings estimate is on file.
  • The next earnings date is not yet scheduled in the calendar we read.

Checked against the records this page reads, on the dates shown above.

5 · Peer comparison

How does Teva Pharmaceutical Industries compare with its peers?

Short answer

Teva Pharmaceutical Industries's score ranks 11th of 13 in the bounded comparison shown, against 12 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.

Teva combines the manufacturing breadth of a global generics supplier with named specialty franchises, biopharmaceutical products, active pharmaceutical ingredients, and collaborative drug development. Its dosage forms range from tablets and injectables to inhaled, transdermal, and topical products.

Product sales dominate the reporting mix, while distribution and licensing add smaller revenue streams. That makes Teva different from a pure royalty biotechnology company and from a narrowly focused branded drugmaker: manufacturing scale and commercial breadth matter alongside the performance of individual specialty medicines.

Peer set — price, market value and MoonshotScore
CompanyPriceMarket valueScore
Lantheus Holdings, Inc. (LNTH) Same industry, near in market value$102.00 Nov 18, 2026$6.67B96 5-pillar Nov 18, 2026
DexCom, Inc. (DXCM) Named competitor$80.19 Nov 19, 2026$29.9B93 5-pillar Nov 18, 2026
Zoetis Inc. (ZTS) Same industry, near in market value$85.57 Nov 18, 2026$34.8B87 5-pillar Nov 18, 2026
Koninklijke Philips N.V. (PHG) Named competitor$29.27 Nov 19, 2026$28.6B78 5-pillar Nov 18, 2026
Dr. Reddy's Laboratories Limited (RDY) Same industry, near in market value$14.85 Nov 19, 2026$12.4B77 5-pillar Nov 18, 2026
Haleon plc (HLN) Same industry, near in market value$9.08 Nov 18, 2026$39.8B75 5-pillar Nov 18, 2026
Supernus Pharmaceuticals, Inc. (SUPN) Same industry, near in market value$28.35 Nov 19, 2026$5.89B74 5-pillar Nov 18, 2026
Takeda Pharmaceutical Company Limited (TAK) Same industry, near in market value$21.27 Nov 18, 2026$68.0B73 5-pillar Nov 18, 2026
Amneal Pharmaceuticals, Inc. (AMRX) Same industry, near in market value$21.88 Nov 18, 2026$7.62B66 5-pillar Nov 18, 2026
Waters Corporation (WAT) Named competitor$456.48 Nov 19, 2026$89.7B60 5-pillar Nov 18, 2026
Teva Pharmaceutical Industries (TEVA) — this page$38.54$45.0B57
Biogen Inc. (BIIB) Named competitor$251.41 Nov 18, 2026$37.2B37 5-pillar Nov 18, 2026
Natera, Inc. (NTRA) Named competitor$289.50 Nov 18, 2026$42.0B36 5-pillar Nov 18, 2026

Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.

Screen more Healthcare stocks

The records behind this page

Analyst targets & estimates

What analysts have on file

Price target, low to high
$44.00 – $54.00
Consensus target
$48.22
Median target
$48.00

Consensus record · Captured .

Measured against a quoted price of $38.54 (as of Nov 19, 2026).

Insider activity

Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026

Transactions
79
Identified insiders
21
Purchases
0
Sales
24
Other transactions
55

Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.

Who holds the shares?

Institutional ownership reported through 13F filings.

Tracked investors

Which of the 16 named investors we follow held TEVA in their latest 13F filing, and what they did against the filing before it.

InvestorManager13F quarterPortfolio weightValueLast quarter
Bridgewater AssociatesFounded by Ray DalioQ3 20260.17%$38.92MNew position
ARK InvestCathie WoodQ3 20260.02%$2.74MNew position
Duquesne Family OfficeStanley DruckenmillerQ3 20260%$0Sold out (was $21.18M)

See all tracked investor portfolios

How to read these figures

These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.

What has been published about Teva Pharmaceutical Industries (TEVA)?

Read these with our analysis →

Common Questions About TEVA (Healthcare)

The last 2 questions are answered from this page's own dated data, not from the research.

Why could AUSTEDO weaken even if Teva’s wider portfolio grows?

Management expects purchasing patterns and the pricing environment ahead of IRA implementation to weigh on AUSTEDO. The broader test is whether other product sales and transformation savings can offset that pressure.

Why did Teva’s profit fall while revenue rose?

The latest period paired higher revenue and gross profit with higher research and selling costs, while operating profit collapsed and the net result turned negative. Sales growth therefore failed to translate into reported profit.

What does Teva sell beyond generic medicines?

Teva sells specialty and biopharmaceutical treatments including AUSTEDO, AJOVY, and Copaxone, respiratory and oncology medicines, and active pharmaceutical ingredients. It also develops long-acting injectable formulations through its MedinCell collaboration.

How does MedinCell fit into Teva’s portfolio?

The collaboration extends Teva’s development portfolio into long-acting injectable formulations, including a risperidone suspension for schizophrenia. It complements the company’s established generics and specialty products rather than replacing either business.

What is the TEVA stock price today?

The last price recorded for Teva Pharmaceutical Industries Limited (TEVA), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.

What is the TEVA price target?

The analyst consensus price target for Teva Pharmaceutical Industries Limited (TEVA), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.

Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.

Sources: the source register lists the 24 figures on this page — 1 from SEC filings and earnings calls, 19 from Financial Modeling Prep (FMP), 3 with no recorded source and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.

Publication details and research sources
Published
Research standards
Methodology · Editorial policy · Corrections

Sources (as of 2026-09-12), by section of the research

  • Summary at the top of the page: Business description; Revenue by segment; Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Cash, investments and debt; Cash against market value
  • 1. What is Teva Pharmaceutical Industries (TEVA), and what does it report?: Sector / industry (provider taxonomy); Business description; Revenue by segment; Management outlook — dated call excerpts
  • 2. What do the latest results show for Teva Pharmaceutical Industries (TEVA)?: Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Reported versus estimated, last 8 quarters; Management outlook — dated call excerpts
  • 3. What are the financial strengths and risks for Teva Pharmaceutical Industries (TEVA)?: Annual revenue and net result (USD millions); Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Cash, investments and debt; Cash and investment components; Cash and short-term investments over time (USD millions); Cash against market value; Trailing twelve-month ratio set; Distress and quality screens; Management outlook — dated call excerpts
  • 4. What should you watch next at Teva Pharmaceutical Industries (TEVA)?: Next earnings report; Analyst revenue and earnings estimates (average); Reported versus estimated, last 8 quarters; Quarterly income statement (USD thousands); Operating cash flow by quarter (USD millions); Management outlook — dated call excerpts
  • 5. How does Teva Pharmaceutical Industries compare with its peers?: Business description; Revenue by segment; Sector / industry (provider taxonomy)
  • FAQ: Why could AUSTEDO weaken even if Teva’s wider portfolio grows?: Management outlook — dated call excerpts; Revenue by segment; Analyst revenue and earnings estimates (average)
  • FAQ: Why did Teva’s profit fall while revenue rose?: Quarterly income statement (USD thousands); Reported versus estimated, last 8 quarters
  • FAQ: What does Teva sell beyond generic medicines?: Business description; Revenue by segment
  • FAQ: How does MedinCell fit into Teva’s portfolio?: Business description; Revenue by segment
Data Sources & Methodology
Figures come from Financial Modeling Prep (FMP). If FMP has no figure for a ticker, a price or fundamental may come from a Yahoo Finance fallback, or a price from an Alpaca fallback. SEC EDGAR is used only for filing links and company identity details (legal name, address), never for figures. AI analysis by Stock Expert AI proprietary algorithms. Technical indicators via industry-standard calculations. Last updated: .
Data Provenance
Sources: Financial Modeling Prep (FMP) — Primary · Yahoo Finance — Fallback · Alpaca — Tertiary
Last fetched:
Cache TTL: Quote 5min · Profile 7d · Financials 7d · Insider 48h
How we use AI: Numbers are pulled directly from FMP & Yahoo Finance — our AI writes the analysis, it never edits the figures.

ETFs that hold TEVA

Funds in our ETF coverage that list TEVA among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.

ETFWeightHoldings as of
VanEck Israel ETF (ISRA)11.43%
WCMI ETF3.30%